Interleukin-6 and new strategies for the treatment of cancer, hyperproliferative diseases and paraneoplastic syndromes
- 5 August 2005
- journal article
- review article
- Published by Taylor & Francis in Emerging Therapeutic Targets
- Vol. 9 (4) , 737-752
- https://doi.org/10.1517/14728222.9.4.737
Abstract
Interleukin-6 (IL-6) is a pleiomorphic cytokine whose growth factor properties play an important role in the development and progression of many types of cancer. IL-6 is produced in response to a variety of stimuli, and is required for the development of T and B lymphocytes to effector cells. In certain neoplasias, such as multiple myeloma, IL-6 is both produced and required for survival by the cancer cell itself. In other neoplasias, IL-6 may come from tissue surrounding the tumour. Thus, therapeutic strategies aimed at inhibiting the production, expression or action of IL-6 would be quite beneficial in the treatment of cancer. Moreover, IL-6 is a pathophysiological factor in several hyperproliferative diseases and the paraneoplastic syndromes that often accompany cancer, such as cachexia and osteoporosis; thus, anti-IL-6 therapy would be useful in treating these entities as well. This expert opinion acquaints the reader with IL-6, its physiological responses, the cancer types with which it is associated...Keywords
This publication has 133 references indexed in Scilit:
- Kaposi's Sarcoma-associated Herpesvirus-encoded Viral Interleukin-6 Is Secreted and Modified Differently Than Human Interleukin-6Journal of Biological Chemistry, 2004
- A novel hIL-6 antagonist peptide from computer-aided design contributes to suppression of apoptosis in M1 cellsPublished by Elsevier ,2004
- Inhibition of gp130 Signaling in Breast Cancer Blocks Constitutive Activation of Stat3 and Inhibits in Vivo MalignancyCancer Research, 2004
- Interleukin-6–dependent gene expression profiles in multiple myeloma INA-6 cells reveal a Bcl-2 family–independent survival pathway closely associated with Stat3 activationBlood, 2004
- Matching SOCS with functionNature Immunology, 2003
- Cross-Talk between Signal Transducer and Activator of Transcription 3 and Androgen Receptor Signaling in Prostate Carcinoma CellsBiochemical and Biophysical Research Communications, 2001
- Protein Inhibitor of Activated STAT3 Regulates Androgen Receptor Signaling in Prostate Carcinoma CellsBiochemical and Biophysical Research Communications, 2000
- Cloning and Characterization of Novel CIS Family GenesBiochemical and Biophysical Research Communications, 1997
- Pharmacological investigations with different protein kinase C inhibitors on IgE-dependent and IgE-independent activation of human basophilsInflammation Research, 1993
- Anti‐human interleukin‐6 receptor antibody inhibits human myeloma growth in vivoEuropean Journal of Immunology, 1992